RxDoctor Payments Data

Salih Colakoglu, MD

Plastic and Reconstructive Surgery · Baltimore, MDNPI 1043509748

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,745 of the $4,480 with a category attached, or 83.6%. 10 manufacturers reported payments, led by TELA Bio, Inc. at 34.1% of the total. 2025 is the largest year on record at $1,755, more than ten times the $125 reported in 2019.

$4,480in general payments, 2019–2025

Across 33 payments — averaging $135.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • TELA Bio, Inc.$2K
  • Davol Inc.$1K
  • AbbVie$749
  • Aroa Biosurgery Incorporated$207
  • Axogen$205
  • Kerecis Limited$203
  • plus $558 from 4 others
$27,302in research payments, 2019–2025

Across 1 payment — averaging $27,302 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$27K

What the payments were for

  • Travel & lodging$73516%
  • Food & beverage$3,74584%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,480 in reported general payments places this provider in the 75th percentile of 55 plastic and reconstructive surgery providers in Maryland.

See all plastic and reconstructive surgery providers in Maryland

Medicare billing

Part B allowed, 2024
$104,983
Medicare patients
87
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other plastic and reconstructive surgery in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →